免责声明: 本站汇总 FDA、ClinicalTrials.gov、PubMed、SEC EDGAR 等官方公开数据,仅供一般参考,不构成医疗建议、诊断、治疗建议或投资建议。

FDA 510(k)

0.9% 氯化钠注射剂,USP BD PosiFlush SF 注射器

K号: K153481 · 2016-04-04

决定日期2016-04-04
产品代码NGT
咨询委员会医疗设备监管文本翻译如下: HO 请注意,由于您没有提供具体的医疗设备监管文本内容,以上仅为示例。请提供具体的文本内容以便进行准确的翻译。
决定实质等同

器械摘要

0.9% Sodium Chloride Injection, USP BD PosiFlush SF Syringe is the device name listed in this FDA 510(k) record. The listed applicant is Becton, Dickinson and Company. It received FDA 510(k) clearance on 2016-04-04 under 510(k) number K153481. The device is classified under product code NGT. It was reviewed by the HO advisory panel. FDA Decision: Substantially Equivalent.

常见问题

What is the 0.9% Sodium Chloride Injection, USP BD PosiFlush SF Syringe?

0.9% Sodium Chloride Injection, USP BD PosiFlush SF Syringe is a medical device that received FDA 510(k) clearance on 2016-04-04. The listed applicant is Becton, Dickinson and Company. The 510(k) number is K153481.

When did 0.9% Sodium Chloride Injection, USP BD PosiFlush SF Syringe receive FDA 510(k) clearance?

0.9% Sodium Chloride Injection, USP BD PosiFlush SF Syringe received FDA 510(k) clearance on 2016-04-04, under 510(k) number K153481.

Who is the listed applicant for 0.9% Sodium Chloride Injection, USP BD PosiFlush SF Syringe?

The FDA 510(k) record lists Becton, Dickinson and Company as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for 0.9% Sodium Chloride Injection, USP BD PosiFlush SF Syringe?

The FDA product code for 0.9% Sodium Chloride Injection, USP BD PosiFlush SF Syringe is NGT.

相关临床试验

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系;请查阅链接的官方来源。

列明Becton, Dickinson and Company为申报人的其他记录

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系;请查阅链接的官方来源。

查看所有 102 个设备 →

相关器械(代码:NGT)

关联记录通过名称、产品代码或其他元数据自动匹配。匹配不意味着已验证临床、科学、企业或监管关系;请查阅链接的官方来源。

官方来源

在 FDA 数据库中查看 →

数据来源于FDA开放API。如需最新且权威的信息,请务必参考官方记录。

↑